Literature DB >> 34002452

Bariatric surgery and the liver-Mechanisms, benefits, and risks.

Sander Lefere1,2, Louis Onghena3,4, Aude Vanlander4, Yves van Nieuwenhove3, Lindsey Devisscher2, Anja Geerts1.   

Abstract

The prevalence of obesity and metabolic diseases such as type 2 diabetes and nonalcoholic fatty liver disease (NAFLD) has risen dramatically over the past decades. At present, bariatric surgery is the most effective treatment for this global health problem, through effects on food intake, gut hormone secretion, metabolic signaling pathways, and adipose tissue dysfunction. The liver occupies a central role in carbohydrate, protein, and lipid metabolism. Notably, a reduction in hepatic fat content and an improvement in hepatic insulin resistance are among the earliest beneficial effects of bariatric surgery, which has therefore emerged as an attractive treatment option for NAFLD. However, as the scope and popularity of weight loss surgery have expanded, new questions have arisen regarding its safety in patients with liver cirrhosis, the outcome of liver transplantation in patients with a history of bariatric surgery, and over incidental reports of liver failure following surgery. Studies in humans and rodents have also linked bariatric surgery to an increased risk of developing alcohol use disorder, a major risk factor for liver disease. This review integrates data from clinical and translational research to delineate both the beneficial impact of bariatric surgery on the liver and the potential risks involved.
© 2021 World Obesity Federation.

Entities:  

Keywords:  RYGB; liver transplantation; nonalcoholic fatty liver disease; sleeve gastrectomy

Year:  2021        PMID: 34002452     DOI: 10.1111/obr.13294

Source DB:  PubMed          Journal:  Obes Rev        ISSN: 1467-7881            Impact factor:   9.213


  6 in total

1.  Changes in interstitial cells and gastric excitability in a mouse model of sleeve gastrectomy.

Authors:  Suk Bae Moon; Sung Jin Hwang; Sal Baker; Minkyung Kim; Kent Sasse; Sang Don Koh; Kenton M Sanders; Sean M Ward
Journal:  PLoS One       Date:  2022-06-23       Impact factor: 3.752

2.  Transcriptomics Reveals Discordant Lipid Metabolism Effects between In Vitro Models Exposed to Elafibranor and Liver Samples of NAFLD Patients after Bariatric Surgery.

Authors:  Joost Boeckmans; Alexandra Gatzios; Anja Heymans; Matthias Rombaut; Vera Rogiers; Joery De Kock; Tamara Vanhaecke; Robim M Rodrigues
Journal:  Cells       Date:  2022-03-04       Impact factor: 6.600

3.  Integrative analyses of hub genes and their association with immune infiltration in adipose tissue, liver tissue and skeletal muscle of obese patients after bariatric surgery.

Authors:  Kemin Yan; Pengyuan Zhang; Jiewen Jin; Xin Chen; Hongyu Guan; Yanbing Li; Hai Li
Journal:  Adipocyte       Date:  2022-12       Impact factor: 3.553

Review 4.  Obesity Management in the Primary Prevention of Hepatocellular Carcinoma.

Authors:  Elizabeth R M Zunica; Elizabeth C Heintz; Christopher L Axelrod; John P Kirwan
Journal:  Cancers (Basel)       Date:  2022-08-22       Impact factor: 6.575

5.  Lower ghrelin levels does not impact the metabolic benefit induced by Roux-en-Y gastric bypass.

Authors:  Yuan Liang; Ruili Yu; Rui He; Lijun Sun; Chao Luo; Lu Feng; Hong Chen; Yue Yin; Weizhen Zhang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-23       Impact factor: 6.055

6.  The Effect of Roux-en-Y Gastric Bypass on Non-Alcoholic Fatty Liver Disease Fibrosis Assessed by FIB-4 and NFS Scores-An 11.6-Year Follow-Up Study.

Authors:  Elfrid Christine Smith Sandvik; Kristin Matre Aasarød; Gjermund Johnsen; Dag Arne Lihaug Hoff; Bård Kulseng; Åsne Ask Hyldmo; Hallvard Græslie; Siren Nymo; Jorunn Sandvik; Reidar Fossmark
Journal:  J Clin Med       Date:  2022-08-21       Impact factor: 4.964

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.